MHB046C

MHB046C is an investigational drug being evaluated in a first-in-human, open-label, multicenter Phase I/II clinical study for the treatment of **advanced solid tumors**. The trial is designed to assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of MHB046C as monotherapy. The development program is structured in two parts: a dose escalation phase (to determine maximum tolerated dose and PK profile) and an indication expansion phase (to further evaluate safety and efficacy in specific advanced solid tumor types)[1][3][5][7]. MHB046C is administered by injection. The precise mechanism of action and molecular modality have not been explicitly disclosed in publicly available sources as of July 2025.